Edition:
India

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

4.56EUR
22 Jun 2018
Change (% chg)

€-0.16 (-3.47%)
Prev Close
€4.73
Open
€4.75
Day's High
€4.75
Day's Low
€4.55
Volume
93,419
Avg. Vol
147,619
52-wk High
€11.15
52-wk Low
€4.05

Chart for

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.61
Market Cap(Mil.): €367.11
Shares Outstanding(Mil.): 40.79
Dividend: --
Yield (%): --

Financials

  ABS.PA Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.72 -- --
ROI: -86.39 14.84 14.38
ROE: -332.06 16.34 16.08

BRIEF-AB Science FY Operating Loss Down At 28.4 Million Euros

* FY NET LOSS EUR 27.1 MILLION VERSUS LOSS OF EUR 27.7 MILLION YEAR AGO

30 Apr 2018

BRIEF-AB Science Announces Negative Opinion From CHMP

* REG-AB SCIENCE ANNOUNCES THAT THE CHMP HAS ADOPTED A NEGATIVE OPINION FOR THE MARKETING AUTHORIZATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS

19 Apr 2018

BRIEF-Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size

* REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE

04 Jan 2018

Earnings vs. Estimates